SCI
19June
RandomizedStudyonDoseEscalationinDefinitiveChemoradiationforPatientsWithLocallyAdvancedEsophagealCancer(ARTDECOStudy)
MaartenC.C.M.Hulshof,ElisabethD.Geijsen,TomRozema,VeraOppedijk,JeroenBuijsen,KarenJ.Neelis,JoostJ.M.E.Nuyttens,MauriceJ.C.vanderSangen,PaulM.Jeene,JannieG.Reinders,MarkI.vanBergeHenegouwen,AdrianaThano,JeaninE.vanHooft,HannekeW.M.vanLaarhoven,AtevanderGaast.Sexdisparitiesmatterincancerdevelopmentandtherapy.JClinOncol.
CORRESPONDENCETO:m.c.hulshof
amsterdamumc.nl.PURPOSE目的Toanalyzetheeffectofradiationdoseescalationtotheprimarytumoronlocaltumorcontrolindefinitivechemoradiation(dCRT)forpatientswithesophagealcancer.
分析在食管癌患者根治性放化疗(dCRT)中，原发肿瘤的放射剂量递增对局部肿瘤控制的影响。
PATIENTSANDMETHODS病人与方法Patientswithmedicallyinoperableand/orirresectableesophagealcarcinoma,referredfordCRT,wererandomlyassignedbetweenastandarddose(SD)of50.4Gy/1.8Gyfor5.5weekstothetumorandregionallymphnodesandahighdose(HD)uptoatotaldoseof61.6Gytotheprimarytumor.Chemotherapyconsistedofcoursesofconcurrentcarboplatin(areaunderthecurve2)andpaclitaxel(50mg/m2)inbotharmsonceaweekfor6weeks.Theprimaryendpointwaslocalprogression-freesurvival.
因无法手术和/或不可切除而转行dCRT的食管癌患者，随机分配于持续5.5周以50.4Gy/1.8Gy为剂量照射肿瘤和区域淋巴结的标准剂量组(SD)和以61.6Gy为总剂量照射原发肿瘤的高剂量(HD)组。化疗部分包括在两组内同时使用卡铂（曲线2下面积）和紫杉醇（50mg/m2），每周一次，持续6周。主要终点是局部无进展生存期。
RESULTS结果BetweenSeptemberandJune,patientswereincluded.Squamouscellcarcinoma(SCC)waspresentin61%ofpatients,and39%hadadenocarcinoma(AC).Radiationtreatmentwas